

THE UNIVERSITY OF TEXAS
MD ANDERSON
CANCER CENTER

CURRICULUM VITAE

Sushovan Guha, MD, PhD

PRESENT TITLE AND AFFILIATION

Primary Appointment

Assistant Professor, Gastroenterology, Hepatology and Nutrition,
The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, Department of Internal Medicine, Texas A&M Health Science Center,
College of Medicine, Houston, TX

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 1466
Houston, TX 77030
Room Number: FCT13.6002
Phone: 713-745-7566
Fax: 713-745-9295
Email: sguha@mdanderson.org

EDUCATION

Degree-Granting Education

University of Madras, Madras, India, MD, 1988, Medicine
Columbia University, New York, NY, MA, 1995, Microbiology and Immunology
Columbia University, New York, NY, MPhil, 1995, Microbiology and Immunology
Molecular Biology Institute, UCLA, Los Angeles, CA, PHD, 2005, Molecular Biology

Postgraduate Training

Internship, Jawaharlal Institute of Post Graduate Medical Education & Research Hospital,
Pondicherry, India, 2/1987–2/1988
Fellowship in Pathology, University of Illinois School of Medicine, Chicago, IL, 5/1989–5/1992
Graduate Student, Department of Microbiology and Immunology, Columbia University, New York,
NY, 6/1992–6/1995
Internship and Residency in Internal Medicine, Albert Einstein College of Medicine Affiliated
Hospitals, New York, NY, 7/1995–6/1998
Specialty Training and Advanced Research (STAR) Fellow in Gastroenterology, David Geffen
School of Medicine at UCLA, Los Angeles, CA, 7/1998–6/2003
Specialty Training and Advanced Research (STAR) Fellowship/Graduate Student, Molecular
Biology Institute, UCLA, Los Angeles, CA, 9/1999–6/2005

CREDENTIALS

Board Certification

American Board of Internal Medicine, 1998–2018, Recertification Date: 2008

American Board of Internal Medicine, Gastroenterology, 2008–2018

Licensures

Active

India, 48953, 3/1991

CA, A66347, 8/1998–12/2009

TX, M1728, 8/2005–8/2010

Inactive

IN, 01047619A, 9/1997

EXPERIENCE/SERVICE

Academic Appointments

Medical House Officer, Medical Intensive Care Unit and Emergency Room, Jawaharlal Institute of Post-Graduate Medical Education & Research Hospital, Pondicherry, India, 1/1988–1/1989

Clinical Instructor, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, 1/2002–1/2004

Assistant Professor in Residence, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, 5/2004–5/2005

Assistant Professor, Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2005–present

Assistant Professor, Department of Internal Medicine, Texas A&M Health Science Center, College of Medicine, Houston, TX, 9/2010–present

Administrative Appointments/Responsibilities

N/A

Other Appointments/Responsibilities

Teaching Assistantship, Columbia University, New York, NY, 9/1993–5/1994

Research Assistantship, Department of Microbiology and Immunology, Columbia University, New York, NY, 6/1994–6/1995

Member, Pancreatic Cancer Working Group, Houston, TX, 2006–present

Member, Botanical Research Center Group at The UT MD Anderson Cancer Center, Houston, TX, 2006–present

Member, Barrett's Esophagus and Esophageal Cancer SPORE group, Houston, TX, 2007–present

Research Awards Panel Member, AGA Institute, Bethesda, MD, 6/2011–5/2013

Endowed Positions

N/A

Consultantships

Vantari Biosciences, inc., San Diego, CA, Consultant, 2007–2008

Drais Pharmaceuticals, Inc., Bridgewater, NJ, Consultant, 1/2009–12/2009

Military or Other Governmental Service

N/A

Institutional Committee Activities

Specialty Training and Advanced Research (STAR) Fellowship Committee in Gastroenterology, Fellow Member Representative, 1998–2004

GI Mucosal Pathology Conference, Assistant Director, 2000–2005

CURE: Digestive Diseases Research Center, Member, 2003–2005
UT GI Fellows Training Committee, Member, 7/2005–present
Institutional Animal Care and Use Committee, Member, 1/2006–5/2007
Division of Internal Medicine Research Committee, Member, 7/2006–present
Nutritional Research Committee, Co-investigator, 7/2008–present
India Steering Committee-Global Academic programs at UT MDACC, Clinical Member, 9/2008–present
Institute of Personalized Cancer Therapy (IPCT)-GI Cancer, Member, 9/2008–present
UT GI Fellowship Program, Site Director-MDACC, 3/2010–present
Multidisciplinary Research Advisory Committee, Member, 3/2010–present
Graduate Medical Education (GME), Member, 3/2010–present
GME Institutional Review Subcommittee, Member, 3/2010–present

HONORS AND AWARDS

Academic Prize in Biochemistry, University of Madras, India, 1982
National Merit Scholar, Government of India, 1982–1988
Academic Prize in Physiology, University of Madras, India, 1983
Academic Prize in Microbiology, University of Madras, India, 1984
Academic Prize in Pathology, University of Madras, India, 1984
Academic Prize in Medicine, University of Madras, India, 1986
Medal of Special Honor, Jawaharlal Institute of Post Graduate Medical Education & Research, India, 1988
Leo M. Davidoff Society Award for Best Intern, Albert Einstein College of Medicine Hospitals, New York, 1996
Best Resident Award, Albert Einstein College of Medicine Hospitals, New York, 1997
Chief Residency Award, Albert Einstein College of Medicine Hospitals, New York, 1998
STAR Fellowship in Gastroenterology, UCLA Medical Center, 1998–2005
Janssen Motility Travel Award for GI Fellows, UCLA, 2000
Eisai-Janssen Fellowship Award, UCLA, 2001
Janssen Guest Fellow Award, UCLA, 2001
Wyeth-Ayerst Travel Fellowship Award, UCLA, 2001
AACR/AFLAC Scholar-in-Training Award, AACR/AFLAC, 2004
AGA Mentors Research Scholar Award, AGA-FDHN, 2004–2007
MDACC Physician Scientist Program, UT MD Anderson Cancer Center (UT MDACC), 2005–present
REGAL (Research Excellence in GI and Liver) Awards, AGA, 2005
R. L. Hirshberg Award in Pancreatic Cancer Research (Basic Science), APA Meeting, 2007
Cyrus Scholar Award-Basic Science, Division of Internal Medicine-UT MDACC, 2008–2011
Cyrus Scholar Award-Basic Science, Division of Internal Medicine-UT MDACC, 2009–2012

RESEARCH

Grants and Contracts

Funded

Principal Investigator, 80%, G protein-coupled receptors: novel targets in pancreatic cancer, 3-0040405, UT MDACC PSP, 9/1/2005–8/31/2010, \$1,250,000 (\$250,000/year)

Co-Investigator, Role of CXCR2 ligands/CXCR2 biological axis in pancreatic cancer, 19809, Mayo Clinic IRG, 9/1/2007–8/31/2009, \$11,550 (\$5,775/year)

Principal Investigator-MDACC, 5%, Biological role of lipocalin 2 in pancreatic cancer, 2P30DK056338-06, NIH/NIDDK, PI - Dr. M. Estes, 3/1/2008–2/28/2009, \$25,000 (\$25,000/year)

Principal Investigator, 5%, Biological role of neutrophil gelatinase associated lipocalin in pancreatic cancer, 326219, UT MDACC IRG, 10/1/2008–9/30/2009, \$50,000 (\$50,000/year)

Co-Investigator, 5%, Biological and therapeutic significance of TG2 in pancreatic cancer, 1-R21-CA135218-01, NIH/NCI, PI - Dr. K. Mehta, 5/1/2009–4/30/2011, \$250,000 (\$125,000/year)

Pending

Co-Investigator, 20%, TG2 in growth, development, and progression of pancreatic cancer, 1-R01-CA131062-01, NIH/NCI, PI - Dr. K. Mehta, 12/1/2007–11/30/2012, \$1,250,000 (\$250,000/year)

Collaborator, 10%, Targeting the microenvironment of NSCLC with kinase inhibitors, 5-P50-CA070907, NIH/NCI, PI - Dr. J. Minna and Dr. J. Roth, 7/1/2008–6/30/2013, \$90,000 (\$18,000/year)

Co-Investigator, Interplay of oxidative DNA damage repair and inflammation in pancreatic carcinoma, NIH/NCI, 10/5/2008–9/30/2010, \$37,708 (\$18,854/year)

Principal Investigator, 15%, Biological Role of Lipocalin 2 in Pancreatic Cancer, 1R21CA143741-01, NIH/NCI, 12/1/2009–11/30/2011, \$250,000 (\$125,000/year)

Career Development Program Awardee, SPORE in Pancreatic Cancer, 5P20CA101936-05, NIH/NCI, PI - Dr. J. L. Abbruzzese, 3/1/2010–2/28/2015, \$250,000 (\$50,000/year)

Principal Investigator, 15%, Role of CXC-chemokines/CXCR2 Biological Axis in Pancreatic Cancer, 1R01CA148775-01, NIH/NCI, 4/1/2010–3/31/2015, \$1,250,000 (\$250,000/year)

Project Leader, 15%, Prevention of colorectal cancer by dietary botanicals, X02-AT-005680/BRC P50, NIH/NCCAM, PI - Aggarwal BB, 7/1/2010–6/30/2015, \$5,000,000 (\$1,000,000/year)

Other

N/A

Completed

Co-Investigator, 20%, Neurotensin mediated signaling pathways in pancreatic cancer, 5-P30-DK41301, NIH/NIDDK, 2/1/2002–11/30/2004, \$50,000 (\$25,000/year)

Principal Investigator, 20%, Synergy between Neurotensin and EGF in promoting mitogenic signaling and cellular proliferation of human pancreatic cancer, 10-05-11531, AGA Research Scholar Award, 7/1/2004–6/30/2007, \$195,000 (\$65,000/year)

Co-Investigator, 10%, G Protein coupled receptors: novel targets in pancreatic cancer, 5-P30-CA016672-30, NIH/NCI, PI - Dr. J. Mendelsohn, 7/1/2005–6/30/2006, \$50,000 (\$50,000/year)

Not Funded

N/A

Protocols

Funded

Collaborator, A randomized double blinded study of curcumin with pre-operative capecitabine and radiation therapy followed by surgery for rectal cancer, 2006-0644, PI - Sunil Krishnan, MD, 2008–present, Gateway for Cancer Research Foundation

Co-Principal Investigator, Molecular and cytologic marker analysis of pancreatic cyst fluid in patients undergoing EUS guided FNA of cystic pancreatic lesions, LAB-08-0164, PI - Dr. M. S. Bhutani, 2008–present, Institutional fund

Collaborator, Screening for early pancreatic neoplasia in high risk individuals: The Lustgarten Foundation-NCI SPORE Cancer of the Pancreas Screening Study (CAPS3), 2007-0193, 2008–present, NIH/NCI/Lustgarten Foundation

Collaborator, Phase I trial of vorinostat and radiation therapy in patients with locally advanced pancreatic cancer, 2008-0780, PI - Sunil Krishnan, MD, 2009–present, Merck

Unfunded

Co-Principal Investigator, Efficacy of an oral formula containing glutamine and TGF-B (Clinutren Protect®) in prevention of chemotherapy-induced toxicity in patients with digestive neoplasm, 2007-0652, PI - Dr. D. Martin, 2008–present, Nestle

Principal Investigator, Presence of Barrett's esophagus in esophageal adenocarcinoma, DR08-0870, 2009–present

Patents and Technology Licenses

Patents

UT MD Anderson Cancer Center, Kapil Mehta, Amit Verma, Jansina Fok, and Sushovan Guha. Methods for treating cancer by targeting tissue transglutaminase, United States, U.S. 11/867,717 and PCT/US2007/080521, 10/1/2007, Filed

UCLA and JPL, Jagdish Patel and Sushovan Guha. Noninvasive and non-radioactive detection of Helicobacter Pylori infection in stomach, United States, Provisional US Patent No. 09-776540, 2/1/2003, Pending

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

Dutch Cancer Society, NIH, Grant Reviewer, 2007

UTMB NIEHS Center pilot project program, NIH, Grant Reviewer, 2007

University of Southern Nevada, Institutional Grant Reviewer, Principal Reviewer, 2009

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Dunaief J, Strober B, Guha S, Khavari P, Alin K, Luban J, Begemann M, Crabtree G, and Goff SP. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. *Cell* 79(1):119-130, 1994.
2. Strober B, Dunaief J, Guha S, and Goff S. Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. *Molecular and Cell Biology* 16(4):1576-1583, 1996.
3. Ryder N, Guha S, Hines O, Reber H, and Rozengurt E. G protein-coupled receptor signaling in human ductal pancreatic cancer cells: neurotensin responsiveness and mitogenic stimulation. *J Cell Physiol* 186(1):53-64, 2001.
4. Lawrence C, Tuma R, Guha S, Michael H, Lowy FD, and Shuter J. Multiple antibiotic changes during the first 72 hours of hospitalization. *American Journal of Medical Science* 322(2):61-67, 2001.
5. Guha S, Rey O, and Rozengurt E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. *Cancer Research* 62(6):1632-40, 2002.

6. Dulai G, Guha S, Kahn K, Gornbein J, and Weinstein W. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: A systematic review. *Gastroenterology* 122(1):26-33, 2002.
7. Guha S, Lunn J, Santiskulvong C, and Rozengurt E. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. *Cancer Research* 63(10):2379-87, 2003.
8. Okada Y, Eibl G, Guha S, Duffy J, Reber H, and Hines OJ. Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. *Clinical and Experimental Metastasis* 21(4):285-292, 2004.
9. Guha S, Eibl G, Kisfalvi K, Fan R, Burdick M, Reber H, Hines OJ, Strieter R, and Rozengurt E. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. *Cancer Research* 65(7):2738-45, 2005.
10. Kisfalvi K, Guha S, and Rozengurt E. Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. *J Cell Physiol* 202(3):880-90, 2005.
11. Chakraborty A, White S, and Guha S. Granulocyte colony-stimulating receptor promotes beta1-integrin-mediated adhesion and invasion of bladder cancer cells. *Urology* 68(1):208-13, 2006.
12. Krishnan S, Rana V, Janjan N, Abbruzzese J, Gould M, Das P, Delclos M, Palla S, Guha S, Varadhachary G, Evans D, Wolff R, and Crane C. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. *Cancer* 107(11):2589-96, 2006.
13. Bhutani M, Pathak A, Nair A, Kunnumakkara A, Guha S, Sethi G, and Aggarwal B. Capsaicin is a novel blocker of constitutive and IL-6 inducible STAT-3 activation: its role in suppression of proliferation and of chemoresistance through the regulation of cell survival gene products in human multiple myeloma cells. *Clinical Cancer Research* 13(10):3024-3032, 2007.
14. Song S, Guha S, Liu K, Buttar N, and Bresalier R. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signaling pathways in Barrett's esophagus and esophageal carcinoma. *Gut* 56(11):1512-1521, 2007.
15. Guha S, Kunnumakkara A, Krishnan S, Diagaradjane P, Gelovani J, and Aggarwal B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. *Cancer Research* 67(8):3853-3861, 2007.
16. Chakraborty A and Guha S. G-CSF/G-CSFR biological axis promotes survival and growth of bladder cancer cells. *Urology* 69(6):1210-1215, 2007.
17. Pathak A, Bhutani M, Nair A, Ahn K, Chakraborty A, Guha S, Sethi G, and Aggarwal B. Ursolic acid inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells by inhibiting constitutive and IL-6 inducible STAT-3 activation pathway. *Molecular Cancer Research* 5(9):943-955, 2007.
18. Yen C, Izzo J, Lee D, Guha S, Wei Y, Wu T, Chen C, Kuo H, Chou C, Hsu J, Sun H, DeMars C, Buttar N, Wang K, Huang P, Ajani J, and Hung M. Bile acid exposure causes upregulation of TSC1/mTOR signal pathway in Barrett's esophagus-associated esophageal adenocarcinoma. *Cancer Research* 68(8):2632-2640, 2008.
19. Kunnumakkara A, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal B, and Krishnan S. Curcumin sensitizes human colorectal cancer xenograft in nude mice to gamma-radiation by targeting NF-kB regulated gene products. *Clinical Cancer Research* 14(7):2128-2136, 2008.
20. Tong Z, Kunnumakkara A, Wang H, Matsuo Y, Diagaradjane P, Harikumar K, Ramachandran V, Sung B, Chakraborty A, Bresalier R, Logsdon C, Aggarwal B, Krishnan S, and Guha S. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. *Cancer Research* 68(15):6100-6108, 2008.
21. Verma A, Guha S, Koul D, Gao Y, Wang H, Abbruzzese J, and Mehta K. Regulation of tumor suppressor protein PTEN by tissue transglutaminase: mechanistic linkage and prognostic significance in pancreatic cancer. *Clinical Cancer Research* 14(7):1997-2005, 2008.

22. Guha S, Verma A, Diagaradjane P, Kunnumakkara A, Sanguino A, Lopez-Berestein G, Sood, A, Aggarwal B, Krishnan S, Gelovani J, and Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. *Clinical Cancer Research* 14(8):2476-2483, 2008.
23. Sung B, Jhurani S, Ahn K, Matsuo Y, Yi T, Guha S, Liu M, and Aggarwal B. Zerumbone downregulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells. *Cancer Research* 68(21):8938-8944, 2008.
24. Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers M, Rashid A, and Maru DM. Anti-phosphorylated Histone H3 expression in Barrett's Esophagus, Low-Grade Dysplasia, High-Grade Dysplasia, and Adenocarcinoma. *Modern Pathology* 22(12):1612-21, 2009.
25. Sung B, Kunnumakkara A, Sethi G, Anand P, Guha S, and Aggarwal B. Curcumin circumvents chemoresistance and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. *Molecular Cancer Therapeutics* 8(4):959-970, 2009.
26. Sandur S, Deorukhkar A, Pandey M, Pabon AM, Shentu S, Guha S, Aggarwal B, and Krishnan S. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF- κ B activity. *International Journal of Radiation Oncology Biology Physics* 75(2):534-42, 2009.
27. Kunnumakkara A, Diagaradjane P, Anand P, Kumar H, Deorukhkar A, Gelovani J, Guha S, Krishnan S, and Aggarwal B. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of Cyclin D1, COX2, MMP9, VEGF, and CXCR4 expression in an orthotopic mouse model. *International Journal of Cancer* 125(9):2187-97, 2009.
28. Matsuo Y, Raimondo M, Woodward TA, Wallace MB, Gill KR, Tong Z, Burdick MD, Yang Z, Strieter RM, Hoffman RM, and Guha S. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. *International Journal of Cancer* 125(5):1027-1037, 2009.
29. Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H, Takeyama H, Tong Z, and Guha S. CXCL8/IL-8 and CXCL12/SDF-1a cooperatively promote invasiveness and angiogenesis in pancreatic cancer. *International Journal of Cancer* 124(4):853-861, 2009.
30. Chen G, Izzo J, Demizu Y, Wang F, Guha S, Wu X, Hung M-C, Ajani JA, and Huang P. Different redox states in malignant and non-malignant esophageal epithelial cells and differential cytotoxic responses to bile acids and honokiol. *Antioxidants and Redox Signaling* 11(5):1083-95, 2009.
31. Maru D, Luthra R, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Correa A, Swisher S, Ajani J, Hofstetter W, and Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. *Cancer* 115(7):1576-1585, 2009.
32. Matsuo Y, Campbell P, Brekken R, Sung B, Ouellette M, Fleming J, Aggarwal B, Der C, and Guha S. K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through MAP kinase signaling pathways. *Molecular Cancer Research* 7(6):799-808, 2009.
33. Harikumar K, Kunnumakkara A, Ahn K, Anand P, Krishnan S, Guha S, and Aggarwal B. Modification of the cysteine residues in I κ B α kinase and NF- κ B (p65) by xanthohumol leads to suppression of NF- κ B-regulated gene products and potentiation of apoptosis in leukemia cells. *Blood* 113(9):2003-2013, 2009.
34. Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H, Takeyama H, and Guha S. Role of pancreatic cancer cells secreted IL-1 α in promoting angiogenesis and its therapeutic implications. *Journal of Surgical Research* 153(2):274-281, 2009.
35. Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Foxton C, Boakes A, Farooq M, Maru D, Diagaradjane P, Matsuo Y, Sinnett-Smith J, Gelovani J, Krishnan S, Aggarwal BB, Rozengurt E, Ireson CR, and Guha S. A novel small molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. *Molecular Cancer Therapeutics* 9(5):1136-46, 2010.

36. Torres-Marquez E, Sinnett-Smith J, Guha S, Kui R, Waldron RT, Rey O, and Rozengurt E. CID755673 enhances mitogenic signaling by phorbol esters, bombesin and EGF through a protein kinase D-independent pathway. *Biochemical and Biophysical Research Communications* 391(1):63-8, 2010.
37. Harikumar K, Sung B, Pandey M, Guha S, Krishnan S, and Aggarwal B. Escin, a Pentacyclic Triterpene, Chemosensitizes Human Tumor Cells through Inhibition of NF- κ B Signaling Pathway. *Molecular Pharmacology* 77(5):818-27, 2010.
38. Kisfalvi K, Hurd C, Guha S, and Rozengurt E. Induced overexpression of protein kinase D1 stimulates mitogenic signaling in human pancreatic carcinoma PANC-1 cells. *Journal of Cellular Physiology* 223(2):309-16, 2010.
39. Matsuo Y, Sawai H, Ochi N, Yasuda A, Sakamoto M, Takahashi H, Funahashi H, Takeyama H, and Guha S. MG132 blocks pancreatic cancer angiogenesis through inhibition of NF- κ B activity. *Digestive Diseases and Sciences* 55(4):1167-76, 2010.
40. Thrower EC, Yuan J, Usmani A, Liu Y, Jones C, Minervini SN, Alexandre M, Pandol SJ, and Guha S. A novel protein kinase D inhibitor attenuates early events of experimental pancreatitis in isolated rat acini. *American Journal of Physiology: Gastrointestinal and Liver Physiology*. In Press.
41. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, and Aggarwal BB. A Phase I/II Study of Complementary Therapy Using Curcumin for Patients with Gemcitabine-Resistant Pancreatic Cancer. *Cancer Chemotherapy and Pharmacology*. In Press.
42. Tong Z, Chakraborty S, Sung B, Koolwal P, Kaur S, Aggarwal BB, Mani SA, Bresalier RS, Batra SK, and Guha S. Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells. *Cancer*. In Press.
43. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, Koca C, Yadav VR, Tong Z, Gelovani J, Guha S, Krishnan S, and Aggarwal BB. Gamma-Tocotrienol Inhibits The Growth of Human Pancreatic Cancer and Sensitizes to Gemcitabine in an Orthotopic Mouse Model Through Modulation of Inflammatory Pathway. *Cancer Research*. In Press.
44. Shibani Pati, Aarif Y. Khakoo, Jing Zhao, Fernando Jimenez, Michael H. Gerber, Matthew Harting, John B. Redell, Raymond Grill, Yoichi Matsuo, Sushovan Guha, Charles S. Cox Jr., Marvin S. Reitz Jr., John B. Holcomb and Pramod K. Dash. Human mesenchymal stem cells inhibit vascular permeability by modulating VE-cadherin/ β -catenin signaling. *Stem Cells and Development*. In Press.
45. Song S, Byrd J, Guha S, Liu K, Koul D, and Bresalier RS. Induction of MUC5AC Mucin by Conjugated Bile Acids in the Esophagus Involves the PI3K/AKT/AP-1 Pathway. *Cancer*. In Press.
46. Ochi N, Tanasanvimon S, Matsuo Y, Tong Z, Sung B, Aggarwal BB, Sinnett-Smith J, Rozengurt E, and Guha S. Protein kinase D1 promotes anchorage-independent growth, invasion, and angiogenesis by human pancreatic cancer cells. *Journal of Cellular Physiology*. In Press.
47. Harikumar K, Kunnumakkara A, Anand P, Sethi G, Diagaradjane P, Krishnan S, Guha S, and Aggarwal B. Resveratrol enhances the antitumor effects of gemcitabine in an orthotopic mouse model of human pancreatic cancer through downmodulation of proliferation and inflammatory markers. *International Journal of Cancer*. In Press.
48. Thosani N, Thosani S, Qiao W, Bhutani MS, and Guha S. Role of EUS-FNA based cytology in diagnosis of pancreatic cyst lesions: A systematic review and meta-analysis. *Digestive Diseases and Sciences*. In Press.
49. Guha S, Tanasanvimon S, Sinnett-Smith J, and Rozengurt E. Role of Protein Kinase D Signaling in Pancreatic Cancer. *Biochemical Pharmacology*. In Press.
50. Harikumar KB, Sung B, Tharakan ST, Pandey MK, Joy B, Guha S, Krishnan S, and Aggarwal BB. Sesamin Manifests Chemopreventive Effects through the Suppression of NF- κ B-regulated Cell Survival, Proliferation, Invasion and Angiogenic Gene products. *Molecular Cancer Research*. In Press.

51. Deorukhkar A, Shujun S, Park H, Diagaradjane P, Puduvali V, Aggarwal B, Guha S, and Krishnan S. Suberoylanilide hydroxamic acid (vorinostat) sensitizes pancreatic cancer cells to radiation by inhibition of DNA repair and radiation-induced EGFR and NF- κ B pro-survival pathways. *Pancreas*. In Press.
52. Richards D, Davis D, Yan P, and Guha S. Unusual Case of Small Cell Gastric Carcinoma: Case Report and Literature Review. *Digestive Diseases and Sciences*. In Press.
53. Shukla S, Shukla A, Guha S, and Mehboob S. Effect of gut flora modulation using prebiotics, probiotics, and synbiotics on minimal hepatic encephalopathy: a meta-analysis. *American Journal of Gastroenterology*. Submitted.
54. Maru D, Correa A, Tong Z, Wang H, Krishnan S, Wu T, Rashid A, Corley L, Swisher S, Ajani J, Hofstetter W, and Guha S. Loss of neutrophil gelatinase associated lipocalin expression in esophageal adenocarcinoma is associated with poor overall survival. *Clinical Cancer Research*. Submitted.
55. Chakraborty A, Guha S, Szymanski S, Fokt I, Helgason T, Kazerooni R, Madden T, and Priebe W. WP1066, a novel JAK2-STAT3 pathway inhibitor promotes apoptosis and blocks growth of bladder cancer cells. *Urology*. Submitted.
56. Guha S, Chakraborty A, Kunnumakkara A, Szymanski S, Fokt I, Abbruzzese J, Kazerooni R, Aggarwal B, Madden T, and Priebe W. WP1066, a potent inhibitor of JAK2-STAT3 pathway inhibits pancreatic tumor growth both in vitro and in vivo. *Cancer*. Submitted.
57. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, Koca C, Tong Z, Jelovani JG, Guha S, Krishnan S, and Aggarwal BB. Zylamend Suppresses Growth and Sensitizes Human Pancreatic Tumors to Gemcitabine in an Orthotopic Mouse Model Through Modulation of Multiple Targets. *Cancer Research*. Submitted.

Invited Articles

1. Guha S, Kaunitz J. Gastroduodenal mucosal defense - an integrated protective response. *Current Opinion in Gastroenterology* 18:650-657, 2002.
2. Rozengurt E, Guha S, Sinnott-Smith J. Gastrointestinal peptide signaling in health and disease. *Eur J Surg Suppl* 587:23-38, 2002.
3. Kunnumakkara AB, Guha S, and Aggarwal BB. Curcumin and colorectal cancer: add spice to your life. *Current Colorectal Cancer Reports* 5:5-14, 2009.
4. Bhutani MS, Verma D, Guha S, Lee JH, Richards-Kortum RR, and Fleming JB. Is Endoscopic Ultrasound "Sound" for Pancreatic Cancer Screening? *Journal of Clinical Gastroenterology*. In Press.
5. Guha S, Matsuo Y. Advances in the Treatment of Angiogenic Pathways in Pancreatic Cancer. *Frontiers in Bioscience*. Submitted.
6. Guha S, Arumugam T, Logsdon C. Molecular biology of pancreatic ductal adenocarcinoma. *Gastrointestinal Cancer Research*. Submitted.

Editorials

1. Bhutani M, Verma D, Guha S, Lee J, Richards-Kortum R and Flemming J. Is endoscopic ultrasound "sound" for Pancreatic Cancer Screening? *Journal of Clinical Gastroenterology*. e-Pub 7/2009.

Other Articles

N/A

Abstracts

1. Dunaief J, Khavari P, Guha S, Alin K, Crabtree G, Goff S. Interaction between the retinoblastoma protein and the human homologue of brahma, a regulator of homeotic genes. *Keystone Tumor Suppressor Genes Symposium, Colorado, 1994*.
2. Strober B, Dunaief J, Guha S, Goff S. The hBRG1 and hBRM transcriptional activators bind to and cooperate with members of the Rb-family of proteins to induce growth arrest. *Keystone Oncogene Symposium, Colorado, 1995*.
3. Guha S, Garrett B, Kovacs TOG. An unusual case of severe bleeding gastric varices from a posterior gastric arteriovenous fistula. *ACG Annual Meeting, New York, NY, 2000*.

4. Dulai G, Guha S, Weinstein W. Most patients with esophageal adenocarcinoma were not previously diagnosed with Barrett's esophagus: a systematic review. AGA DDW Annual Meeting, San Diego, CA, 2000.
5. Guha S, Rozengurt E. Phorbol ester and Neurotensin activate a novel serine-threonine kinase, Protein Kinase D, in human pancreatic ductal cancer cells. CURE Annual Basic and Clinical Science Research Meeting, UCLA, Los Angeles, 2000.
6. Guha S, Rozengurt E. Phorbol ester and Neurotensin activate a novel serine-threonine kinase, Protein Kinase D, in human pancreatic ductal cancer cells. Tyrosine phosphorylation and Cell Signaling meeting, The Salk Institute, La Jolla, CA, 2000.
7. Guha S, Rozengurt E. Neurotensin mediates mitogenic signaling in human pancreatic cancers. ACG Annual Meeting, Las Vegas, NV, 2001.
8. Guha S, Rozengurt E. Protein Kinase C (PKC) plays a pivotal role in neurotensin mediated signaling in human pancreatic ductal cancer cells. AGA DDW Annual Meeting, Atlanta, GA, 2001.
9. Guha S, Rozengurt E. Protein Kinase C (PKC) plays a pivotal role in neurotensin mediated signaling in human pancreatic ductal cancer cells. CURE Annual Basic and Clinical Science Research Meeting, UCLA, Los Angeles, CA, 2001.
10. Guha S, Rozengurt E. Protein Kinase C plays a pivotal role in neurotensin mediated signaling in human ductal pancreatic cancer cells. Practice Management Conference for Gastroenterology Fellows (ASGE), Seattle, WA, 2001.
11. Guha S, Rozengurt E. Protein Kinase C plays a pivotal role in neurotensin mediated signaling in human pancreatic ductal cancer cells. Current Topics in Gastroenterology Meeting, Las Vegas, NV, 2001.
12. Guha S, Rozengurt E. Protein Kinase C plays a pivotal role in neurotensin mediated signaling in human pancreatic ductal cancer cells. Sixth Annual Young Investigators' Conference in Digestive Diseases, Monterey, CA, 2001.
13. Guha S, Rozengurt E. Neurotensin induces protein kinase C-dependent mitogenic signaling in human pancreatic cancers. AGA DDW Annual Meeting, San Francisco, CA, 2002.
14. Guha S, Rozengurt E. Neurotensin induces protein kinase C-dependent mitogenic signaling in human pancreatic cancers. CURE Annual Basic and Clinical Science Research Meeting, UCLA, Los Angeles, CA, 2002.
15. Guha S, Rozengurt E. Neurotensin induces protein kinase C-dependent mitogenic signaling in human pancreatic cancers. Seventh Annual Young Investigators' Conference in Digestive Diseases, Indian Wells, CA, 2002.
16. Guha S, Rey O, Rozengurt E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. AGA DDW Annual Meeting, San Francisco, CA, 2002.
17. Guha S, Kisfalvi K, Rozengurt E. Neurotensin and EGF synergistically stimulate growth of human pancreatic cancer. Eighth Annual Young Investigators' Conference in Digestive Diseases, Phoenix, AZ, 2003.
18. Guha S, Santiskulvong C, Rozengurt E. Neurotensin stimulates PKC-dependent and EGFR-independent ERK activation in pancreatic cancer. AGA DDW Annual Meeting, Orlando, FL, 2003.
19. Guha S, Eibl G, Kisfalvi K, Reber H, Hines O, Rozengurt E. [DArg1, DTrp5,7,9, Leu11]SP: a novel potent inhibitor of mitogenic signaling and growth in vitro and in vivo in human pancreatic cancer. 1st Annual Gastrointestinal Cancers Symposium (ASCO-AGA-ASTRO-SSO), San Francisco, CA, 2004.
20. Guha S, Eibl G, Kisfalvi K, Reber H, Hines O, Rozengurt E. [DArg1, DTrp5,7,9, Leu11]SP: a novel potent inhibitor of mitogenic signaling and growth in vitro and in vivo in human pancreatic cancer. Ninth Annual Young Investigators' Conference in Digestive Diseases, Huntington Beach, CA, 2004.
21. Guha S, Eibl G, Kisfalvi K, Reber H, Hines O, Rozengurt E. Broad-spectrum G protein-coupled receptor antagonist, [DArg1,DTrp5,7,9,Leu11]SP : a novel potent inhibitor of growth and angiogenesis in pancreatic cancer. AGA DDW Annual Meeting, New Orleans, LA, 2004.
22. Guha S, Eibl G, Kisfalvi K, Fan R, Burdick M, Reber H, Hines O, Strieter R, Rozengurt E. Broad-spectrum G protein-coupled receptor antagonist, [DArg1,DTrp5,7,9,Leu11]SP : a dual

- inhibitor of growth and angiogenesis in pancreatic cancer. AGA DDW Annual Meeting, Chicago, IL, 2005.
23. Kisfalvi K, Guha S, Rozengurt E. Synergy between Neurotensin and EGF in mediating ERK activation, DNA synthesis, and anchorage-independent growth in pancreatic cancer. AGA DDW Annual Meeting, Chicago, IL, 2005.
 24. Guha S, Eibl G, Kisfalvi K, Fan R, Burdick M, Reber H, Hines O, Strieter R, Rozengurt E. Broad-spectrum G protein-coupled receptor antagonist, {DArg1, DTrp5,7,9, Leu11}SP: a dual inhibitor of growth and chemokine-mediated angiogenesis in pancreatic cancer. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2006.
 25. Kunnumakkara A, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal B. Curcumin potentiates anti-tumor activity of gemcitabine in an orthotopic model of pancreatic cancer: role in inhibition of NF- κ B and of angiogenesis. ISGIO Annual Meeting, Pentagon City Arlington, VA, 2006.
 26. Guha S, Tong Z, Bresalier R, Hoffman R, Burdick M, Strieter R. CXC-chemokines mediate a novel pathway of angiogenesis in pancreatic cancer. AACR-Lustgarten Foundation for Pancreatic Cancer Research Meeting, Chapel Hill, NC, 2006.
 27. Guha S, Tong Z, Bresalier R, Hoffman R, Burdick M, Strieter R. CXC-chemokines mediate a novel pathway of angiogenesis in pancreatic cancer. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2006.
 28. Guha S, Bresalier R, Hoffman R, Burdick M, Strieter R. CXC-chemokines mediate a novel pathway of angiogenesis in pancreatic cancer. ISGIO Annual Meeting, Pentagon City Arlington, VA, 2006.
 29. Verma A, Guha S, Wang H, Kumar R, Mehta K. Elevated tissue transglutaminase expression confers resistance to gemcitabine and increased metastasis in pancreatic ductal adenocarcinoma: a novel role of tissue transglutaminase. ISGIO Annual Meeting, Pentagon City Arlington, VA, 2006.
 30. Chakraborty A, Tong Z, Helgason T, Liu K, Bresalier R, Guha S. Granulocyte colony stimulating factor receptor promotes B1-integrin mediated adhesion and invasion of pancreatic cancer cells. AGA DDW Annual Meeting, Los Angeles, CA, 2006.
 31. Chakraborty A, Tong Z, Liu K, Bresalier R, Guha S. Granulocyte colony stimulating factor receptor promotes B1-Integrin mediated adhesion and invasion of pancreatic cancer cells. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2006.
 32. Chakraborty A, Tong Z, Liu K, Bresalier R, Guha S. Granulocyte colony stimulating factor receptor promotes B1-Integrin mediated adhesion and invasion of pancreatic cancer cells. ISGIO Annual Meeting, Pentagon City Arlington, VA, 2006.
 33. Kisfalvi K, Guha S, Hurd C, Rozengurt E. Protein Kinase D stimulates mitogenic response and cell proliferation in human pancreatic cancer cells. AGA DDW Annual Meeting, Los Angeles, CA, 2006.
 34. Chakraborty A, Guha S, Helgason T, Szymanski S, Fokt I, Kazerooni R, Madden T, and Priebe W. A novel Jak2/STAT3 pathway inhibitor promotes apoptosis and blocks growth of bladder cancer cells. AACR Annual meeting, Los Angeles, CA, 2007.
 35. Guha S, Matsuo Y, Hoffman R, Burdick M, Strieter R. Blockade of CXC-chemokine receptor 2 inhibits angiogenesis in an orthotopic model of pancreatic cancer. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.
 36. Kunnumakkara A, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal B, Guha S. Curcumin potentiates anti-tumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of NF- κ B regulated gene products. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.
 37. Kunnumakkara A, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal B, Guha S. Curcumin potentiates anti-tumor activity of gemcitabine in an orthotopic model of pancreatic cancer: role in inhibition of proliferation, angiogenesis, and NF- κ B regulated gene products. AGA DDW Annual Meeting, Los Angeles, CA, 2007.
 38. Guha S, Bresalier R, Hoffman R, Burdick M, Strieter R. CXC-chemokines/CXCR2 mediate a novel pathway of angiogenesis in pancreatic cancer. AACR Annual Meeting, Los Angeles, CA, 2007.

39. Matsuo Y, Ochi N, Takeyama H, Sawai H, Okada Y, Manabe T, Guha S. CXCL8/IL-8 and CXCL12/SDF-1a cooperatively promote invasion and angiogenesis of pancreatic cancer. American Pancreatic Association (APA) Annual Meeting, Chicago, Illinois, 2007.
40. Matsuo Y, Ochi N, Takeyama H, Sawai H, Okada Y, Manabe T, Guha S. CXCL8/IL-8 and CXCL12/SDF-1a cooperatively promote invasion and angiogenesis of pancreatic cancer. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.
41. Matsuo Y, Ochi N, Takeyama H, Sawai H, Okada Y, Manabe T, Guha S. CXCL8/IL-8 and CXCL12/SDF-1a cooperatively promote invasion and angiogenesis of pancreatic cancer. Int'l Society of Gastrointestinal Oncology (ISGIO) Annual Meeting, Philadelphia, Pennsylvania, 2007.
42. Guha S, Verma A, Kunnumakkara A, Diagaradjane P, Krishnan S, Gelovani J, Aggarwal B, Lopez-Bernstein G, Mehta K. Inhibition of tissue transglutaminase expression potentiates gemcitabine effects in reducing tumor growth and metastasis in an orthotopic model of pancreatic cancer. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.
43. Tong Z, Matsuo Y, Wang H, Maitra A, Chakraborty A, Krishnan S, Guha S. Neutrophil gelatinase associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. International Society of Gastrointestinal Oncology (ISGIO) Annual Meeting, Philadelphia, Pennsylvania, 2007.
44. Tong Z, Wang H, Guha S. Neutrophil gelatinase associated lipocalin: a novel suppressor of invasion in pancreatic cancer. AGA DDW Annual Meeting, Los Angeles, CA, 2007.
45. Tong Z, Wang H, Chakraborty A, Guha S. Neutrophil gelatinase associated lipocalin: a novel suppressor of invasion in pancreatic cancer. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.
46. Guha S, Verma A, Sood A, Lopez-Berestein G, Mehta K. Transglutaminase-2 (TG2) as therapeutic target for pancreatic cancer. 4th International Tumor Progression and Therapeutic Resistance Meeting, Philadelphia, PA, 2007.
47. Guha S, Chakraborty A, Szymanski S, Fokt I, Abbruzzese J, Kazerooni R, Madden T, Priebe W. WP1066, a potent inhibitor of JAK2/STAT3 pathway inhibits pancreatic cancer growth both in vitro and in vivo. AACR Annual meeting, Los Angeles, CA, 2007.
48. Guha S, Chakraborty A, Szymanski S, Fokt I, Abbruzzese J, Kazerooni R, Madden T, Priebe W. WP1066, a potent inhibitor of JAK2/STAT3 pathway inhibits pancreatic cancer growth both in vitro and in vivo. DoIM Research Retreat, UT MD Anderson Cancer Center, Houston, TX, 2007.
49. Guha S, Chakraborty A, Kunnumakkara A, Slawomir S, Fokt I, Abbruzzese J, Aggarwal B, Madden T, Priebe W. A novel JAK2-STAT3 inhibitor blocks mitogenesis and angiogenesis in pancreatic cancer. AACR, San Diego, CA, 4/2008.
50. Tong Z, Matsuo Y, Kunnumakkara A, Wang H, Chakraborty A, Aggarwal B, Krishnan S, Guha S. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. AACR San Diego, CA, 4/2008.
51. Mehta K, Verma A, Guha S, Fok J, Lopez-Berestein G, Sood A. Therapeutic significance of elevated tissue transglutaminase (TG2) expression in pancreatic cancer. AACR, San Diego, CA, 4/2008.
52. Matsuo Y, Guha S. CXCL8/IL-8 and CXCL12/SDF-1a cooperatively promote invasion and angiogenesis of pancreatic cancer. Digestive Disease Week, San Diego, CA, 5/2008.
53. Guha S, Verma A, Mehta K. Tissue transglutaminase downregulation potentiates gemcitabine efficacy and blocks pancreatic cancer growth in vivo. Digestive Disease Week, San Diego, CA, 5/2008.
54. Raimondo M, Gill K, Wallace M, Woodward T, Matsuo Y, Guha S. Can CXC-chemokines and lipocalin 2 in pancreatic juice (PJ) distinguish chronic pancreatitis (CP) from pancreatic cancer (PC)? APA Annual Meeting, Chicago, IL, 11/2008.
55. Thrower E, Yuan J, Kelly M, Jones C, Pandol S, Guha S. Protein Kinase D: a novel regulator of zymogen activation and amylase secretion in acute pancreatitis. APA Annual Meeting, Chicago, IL, 11/2008.
56. Ireson CR, Harikumar KB, Kunnumakkara AB, Deorukhkar A, Tong Z, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Farooq M, Maru D, Diagaradjane P,

- Matsuo Y, Krishnan S, Gelovani J, Aggarwal BB and Guha S. A novel small molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vivo. AACR Annual Meeting, Denver, CO, 2009.
57. Shukla S, Shukla A, Bhutani M, and Guha S. Colorectal cancer risk in breast cancer survivors: Evidence from a comprehensive cancer center. ACG 2009, San Diego, CA, 2009.
 58. Matsuo Y, Raimondo M, Woodward TA, Wallace MB, Gill KR, Tong Z, Burdick MD, Yang Z, Strieter RM, Hoffman RM and Guha S. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. DDW, Chicago, IL, 2009.
 59. Shukla S, Leisner E, Mehboob S and Guha S. Effects of lactulose treatment in patients with minimal hepatic encephalopathy: A meta-analysis of randomized controlled trials. ACG 2009, San Diego, CA, 2009.
 60. Shukla S, Leisner E, Mehboob S and Guha S. Effects of use of probiotics in minimal hepatic encephalopathy: A meta-analysis of randomized controlled trials. ACG 2009, San Diego, CA, 2009.
 61. Ke S, Wang W, Haldipur AG, Tong Z, Cameron AG, Mawad ME, Matsuo Y, Guha S. Imaging a secretory protein in a pancreatic tumor xenograft model. AACR Annual Meeting, Denver, CO, 2009.
 62. Matsuo Y, Campbell PM, Brekken RA, Sung B, Ouellette MM, Fleming JB, Aggarwal BB, Der CJ and Guha S. K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through MAP kinase signaling pathways. AACR Annual Meeting, Denver, CO, 2009.
 63. Fan X, Lee JH, Sellin J, and Guha S. Prevalence of BE in patients with esophageal adenocarcinoma and its association with cancer location and surveillance program. DDW, Chicago, IL, 2009.
 64. Thrower EC, Yuan J, Kelly M, Jones C, Ireson C, Pandol SJ, and Guha S. Protein kinase D modulates secretagogue-induced zymogen activation and amylase secretion in rat pancreatic acinar cells. DDW, Chicago, IL, 2009.
 65. Thosani N, Thosani S, Qiao W, Bhutani MS, and Guha S. Role of EUS-FNA based cytology in differentiating mucinous versus non-mucinous cystic pancreatic lesions: a systematic review and meta-analysis. DDW, Chicago, IL, 2009.
 66. Kaseb A, Harikumar KB, Kunnumakkara A, Deorukhkar A, Aggarwal BB, Krishnan S, Abbruzzese J, and Guha S. Thymoquinone sensitizes pancreatic cancer cells to gemcitabine by targeting E2F1 dependent cell cycle pathways. AACR Annual Meeting, Denver, CO, 2009.
 67. Ireson CR, Harikumar KB, Kunnumakkara AB, Deorukhkar A, Tong Z, Maru D, Diagaradjane P, Ochi N, Krishnan S, Aggarwal BB, Rozengurt E, Guha S. A novel small molecule inhibitor of Protein Kinase D blocks pancreatic cancer growth both in vitro and in vivo. DDW Annual Meeting, New Orleans, LA (#414), 2010.
 68. Varia AK, Guha S, Hassan M, Kaseb AO. A single multidisciplinary center's experience in the management of hepatitis C virus-induced hepatocellular carcinoma in 184 patients. ASCO Meeting, Chicago IL (#51839), 2010.
 69. Ochi N, Wallace MB, Woodward TA, Matsuo Y, Guha S, Raimondo M. Can lipocalin 2/NGAL in exocrine pancreatic secretions distinguish chronic pancreatitis (CP) from pancreatic cancer (PC)? DDW Annual Meeting, New Orleans LA (#T1401), 2010.
 70. Torres-Marque E, Sinnott-Smith J, Guha S, Rey O, Waldron RT, Rozengurt E. CID755673 enhances mitogenic signaling by Bombesin and EGF through a protein Kinase D-Independent pathway. DDW Annual Meeting, New Orleans LA (#S1700), 2010.
 71. Shukla S, Osowo A, Shukla A, Bhutani M, Guha S. Colorectal cancer risk in breast cancer survivors: a retrospective cohort study. DDW Annual Meeting, New Orleans LA (#S1146), 2010.
 72. Shukla S, Sampath PK, Shukla A, Guha S, Mehboob S. Comparison of probiotics and lactulose as treatment options in hepatic encephalopathy: a Meta-Analysis. DDW Annual Meeting, New Orleans LA (#S1922), 2010.
 73. Song S, Duan X, Hwang RF, Hafley M, Guha S, Logsdon CD, Bresalier RS. Galectin-3 induces human pancreatic stellate cell activation and IL-8 production via NF-kB signaling. DDW Annual Meeting, New Orleans LA (#132), 2010.

74. Kisfalvi K, Sinnott-Smith J, Guha S, Rozengurt E. Induced overexpression of protein kinase D1 stimulates mitogenic signaling in human pancreatic carcinoma PANC-1 cells. DDW Annual Meeting, New Orleans LA (#M1969), 2010.
75. Gupta V, Bektas M, Ross WA, Lee JH, Singh H, Guha S, Oruc N, Kapadia AS, Eng C, Bhutani MS. Is there a correlation between body mass index (BMI) and endoscopic ultrasound (EUS) stage of rectal cancer at initial presentation? DDW Annual Meeting, New Orleans LA (#S113), 2010.
76. Tong Z, Koolwal P, DeMars CJ, Buttar NS, Guha S. Neutrophil gelatinase-associated lipocalin inhibits proliferation of human esophageal adenocarcinoma cells both in vitro and in vivo. AACR 101st Annual Meeting 2010, Washington DC (#3074), 2010.
77. Shukla S, Sampath PK, Shukla A, Guha S, Mehboob S. Use of prebiotics, probiotics and synbiotics in treatment of minimal hepatic encephalopathy: a Meta-Analysis. DDW Annual Meeting, New Orleans LA (#155), 2010.
78. Shukla S, Shukla A, Guha S, Mehboob S. Use of proton pump and risk of clostridium difficile-associated diarrhea: a Meta-Analysis. DDW Annual Meeting, New Orleans, LA (#S1230), 2010.

Book Chapters

1. Guha S. Other GI tumors. In: Gastroenterology and Hepatology: The Modern Clinician's Guide, 1st edition. Weinstein WM, Hawkey CJ, and Bosch J, 2005.
2. Spinn MP, and Guha S. Small Bowel Tumors. In: Textbook of Clinical Gastroenterology and Hepatology, 2nd edition. Wiley-Blackwell. In Press.
3. Arora, G, Wolf D, Bhutani, MS, and Guha S. Gastrointestinal Disease. In: Critical Care for Cancer Patients. Springer: USA. Submitted.

Books (edited and written)

1. Weinstein W, Lewin K, Riddell R. Gastrointestinal Pathology and Its Clinical Implications, 2000.
2. Guha S and Bernstein C. Ed(s) Riddell, R. Gastrointestinal Pathology and Its Clinical Implications, 2nd edition. Series Ed(s) Guha S and Bertsein C. Lippincott Williams & Wilkins. Submitted.
3. Aggarwal BB, Krishnan S, and Guha S. Ed(s) Aggarwal BB, Krishnan S, and Guha S. Inflammation, Life Style and Chronic Diseases: The Silent Link. Taylor and Francis Group, LLC. Submitted.

Letters to the Editor

N/A

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Editorial Board, Current Topics in Gastroenterology, 2001–2002

Member of Editorial Review Board

Editorial Board Member, Digestive Diseases and Science, 2009–present

Editorial Advisory Board Member, Current Medicinal Chemistry, Bentham Science, 2010–present

Journal Reviewer

Reviewer, American Journal of Physiology, 2001–present

Reviewer, Current Opinion in Gastroenterology, 2002–present

Reviewer, European Journal of Surgery, 2002–present

reviewer, Gastroenterology, 2003–present

Reviewer, Pancreas, 2004–present
Reviewer, Pancreatology, 2004–present
Reviewer, Cancer, 2005–present
Reviewer, Cancer Research, 2005–present
Reviewer, Gastroenterology and Hepatology, 2005–present
Reviewer, Journal of National Cancer Institute, 2005–present
Reviewer, American Journal of Physiology-GI physiology, 2007–present
Reviewer, BBA-Gene Regulation, 2007–present
Reviewer, Clinical Cancer Research, 2007–present
Reviewer, European Journal of Immunology, 2007–present
Reviewer, Journal of Gastroenterology and Hepatology, 2007–present
Reviewer, Oncogene, 2007–present
Reviewer, Digestive Diseases and Sciences, 2008–present
Reviewer, Molecular Cancer Research, 2008–present
Reviewer, Molecular Cancer Therapeutics, 2008–present

Other Editorial and Review Activities

Editor, F1000 Medicine, F1000 Ltd., Editorial Board Memembr of Pancreatic Diseases, 2009–present

TEACHING

Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal Teaching

Courses Taught

N/A

Training Programs

Instructor, UT GI fellowship training program, The University of Texas M. D. Anderson Cancer Center, Course Hours: 1
1/2008–present

Other Formal Teaching

Instructor, Teaching GI Fellows-Sleisenger and Fordtran's GI and Liver Disease Textbook, The University of Texas M. D. Anderson Cancer Center, Course Number: Chapter 1
2007–present

Instructor, Teaching GI Fellows-Sleisenger and Fordtran's GI and Liver Disease Textbook, The University of Texas M. D. Anderson Cancer Center, Course Number: Chapter 2
2007–present

Instructor, Teaching GI Fellows-Sleisenger and Fordtran's GI and Liver Disease Textbook, The University of Texas M. D. Anderson Cancer Center, Course Number: Chapter 3
2007–present

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

Research mentor, The University of Texas M. D. Anderson Cancer Center, Pooja Koolwal, BS, 9/2008–6/2009

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

Instructor/Supervisor, Rotating GI Fellows of UT Health Sciences-Houston program, UT-HSC Rotating GI Fellows, 7/2005–present

Other Supervisory Teaching

Research Mentor, The University of Texas M. D. Anderson Cancer Center, Chandra Dasari, MBBS, 9/2008–7/2009

Teaching Outside of Current Institution

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

Instructor, Gastrointestinal cancers: from bench to bedside-Refresher course for GI Fellows, UCLA
2000,

Instructor, Gastrointestinal Pathophysiology Course in School of Nursing, UCLA
2001,

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

Research mentor, UTHSC-Houston, Nirav Thosani, MD, 1/2008–present

Other Supervisory Teaching

David Geffen School of Medicine at UCLA, Pre-Med Biology Student, Do Nguyen, MD, Undergraduate and Allied Health Students, 9/2004–6/2005

Research Mentor, SUNY, Buffalo, NY, Ashish Shukla, MD, 1/2007–present

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

UT MD Anderson Cancer Center, Third Annual Esophageal Cancer and Barrett's Metaplasia Research Summit, Las Vegas, NV, Co-Chair, 11/2006

Society of Translational Cancer Research, Second International Conference on Translational Research: Cancer and Natural Products, Lonavala, Maharashtra, India, Scientific Committee Member, 12/2007

Presentations at National or International Conferences

Invited

Phorbol ester and neurotensin activate a novel serine-threonine kinase, Protein Kinase D, in human pancreatic ductal cancer cells, CURE Annual Basic and Clinical Science Research Meeting at UCLA, Los Angeles, CA, 3/17/2000

Phorbol ester and neurotensin activate a novel serine-threonine kinase, Protein Kinase D, in human pancreatic ductal cancer cells, Tyrosine Phosphorylation and Cell Signaling Meeting at The Salk Institute, La Jolla, CA, 9/15/2000

Protein kinase D in human ductal pancreatic cancer cells (PANC-1): rapid activation by neurotensin through protein kinase C, Current Topics in Gastroenterology Meeting, Las Vegas, NV, 3/1/2001

Protein kinase C plays a pivotal role in neurotensin mediated signaling in human ductal pancreatic cancer cells, CURE Annual Basic and Clinical Science Research Meeting at UCLA, Los Angeles, CA, 3/16/2001

Protein kinase C plays a pivotal role in neurotensin mediated signaling in human ductal pancreatic cancer cells, Sixth Annual Young Investigators' Conference in Digestive Diseases, Monterey, CA, 4/6/2001

Protein Kinase C plays a pivotal role in neurotensin mediated signaling in human ductal pancreatic cancer cells, Practice Management Conference for Gastroenterology Fellows (ASGE), Seattle, WA, 10/12/2001

Neurotensin mediates mitogenic signaling in human pancreatic cancers, ACG Annual Meeting, Las Vegas, NV, 10/22/2001

Neurotensin induces protein kinase C-dependent mitogenic signaling in human pancreatic cancers, CURE Annual Basic and Clinical Science Research Meeting at UCLA, Los Angeles, CA, 3/15/2002

Neurotensin induces mitogenic signaling in human pancreatic cancers, Seventh Annual Young Investigators' Conference in Digestive Diseases, Indian Wells, CA, 4/13/2002

Neurotensin and EGF synergistically stimulate growth of human pancreatic cancer, Eighth Annual Young Investigators' Conference in Digestive Diseases, Phoenix, AZ, 4/11/2003

[DArg1, DTrp5,7,9, Leu11]SP: A novel potent inhibitor of mitogenic signaling and growth in vitro and in vivo in human pancreatic cancer, 1st Annual Gastrointestinal Cancers Symposium, San Francisco, CA, 1/23/2004

[DArg1, DTrp5,7,9, Leu11]SP: A novel potent inhibitor of mitogenic signaling and growth in vitro and in vivo in human pancreatic cancer, Ninth Annual Young Investigators' Conference in Digestive Diseases, Huntington Beach, CA, 4/4/2004

Broad-Spectrum G Protein-Coupled Receptor Antagonist, [DArg1, DTrp5,7,9, Leu11]SP : A Novel Potent Inhibitor of Growth and Angiogenesis in Pancreatic Cancer, AGA Digestive Diseases Week, New Orleans, LA, 5/18/2004

Broad-spectrum G protein-coupled receptor antagonist, [DArg1, DTrp5,7,9, Leu,11]SP : A novel potent inhibitor of growth and angiogenesis in pancreatic cancer, FASEB Meeting on Innovations in GI Research and Therapy, Snowmass, CO, 8/15/2005

Broad-Spectrum G Protein-Coupled Receptor Antagonist, [DArg1, DTrp5,7,9, Leu11]SP : A Dual Inhibitor of Growth and Angiogenesis in Pancreatic Cancer, 4th Annual REGAL Awards Symposium, San Francisco, CA, 10/8/2005

Animal model of Barrett's metaplasia, The Second Annual Esophageal Cancer and Barrett's Metaplasia Research Summit, Las Vegas, NV, 11/12/2005

G protein-coupled receptor mediated signaling pathways in pancreatic cancer, UCLA Division of Digestive Diseases Research Seminar, Los Angeles, CA, 3/9/2006

CXCR2 ligands/CXCR2 biological axis regulates angiogenesis in pancreatic cancer, The AGA 2006 Academic Skills Workshop, Redondo Beach, CA, 3/10/2006

CXC-chemokines mediate a novel pathway of angiogenesis in pancreatic cancer, International Society of Gastrointestinal Oncology Meeting, Pentagon City Arlington, VA, 9/21/2006

Neutrophil gelatinase associated lipocalin: a novel suppressor of invasion in pancreatic cancer, Division of Internal Medicine Annual Research Retreat, MD Anderson Cancer Center, Houston, TX, 5/11/2007

Neutrophil gelatinase associated lipocalin: a novel suppressor of invasion in pancreatic cancer, AGA Digestive Diseases Week, Washington, DC, 5/20/2007

Tissue transglutaminase downregulation potentiates gemcitabine efficacy and blocks pancreatic cancer growth in vivo, ISGIO, Philadelphia, PA, 7/27/2007

Transglutaminase-2 (TG2) as therapeutic target for pancreatic cancer, 4th International Tumor Progression and Therapeutic Resistance Meeting, Philadelphia, PA, 10/5/2007

Tissue transglutaminase downregulation potentiates gemcitabine efficacy and blocks pancreatic cancer growth in vivo, American Pancreatic Association (APA) Meeting, Chicago, IL, 11/1/2007

Guha S, Verma A, and Mehta K. Tissue transglutaminase downregulation potentiates gemcitabine efficacy and blocks pancreatic cancer growth in vivo, Digestive Disease Week (DDW), The UT MD Anderson Cancer Center, 5/2008

IPMN: an update on molecular pathogenesis, Digestive Disease Week (DDW), American Gastroenterological Association, Chicago, IL, 5/31/2009

Botanicals and Cancer Research: Clinical Trials Workshop, NIH, NCI-OCCAM, Bethesda, MD, 7/15/2009

Moderator for Panel Discussion of localized and metastatic pancreatic cancer, ISGIO, International Society of Gastrointestinal Oncology, Philadelphia, PA, 10/1/2009

Guha, S. G protein-coupled receptor mediated signaling pathways in pancreatic cancer, Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Recherches Scientifiques Luxembourg (RSL) a.s.b.l., Luxembourg, Luxembourg, 1/29/2010

Other, Including Scientific Exhibitions

Diseases of the Pancreas, David Geffen School of Medicine at UCLA, Los Angeles, CA, 3/13/2000

NERD Update, Los Angeles Regional Consultants Conference, Astra Pharmaceuticals, L.P., Los Angeles, CA, 10/26/2000

Uninvestigated Dyspepsia, Los Angeles Regional Clinical Conference, Janssen Pharmaceuticals, Los Angeles, CA, 7/26/2001

MALT Lymphoma, Fellows Didactic Lecture Series, David Geffen School of Medicine at UCLA, Los Angeles, CA, 8/10/2001

Molecular Basis of Cancer, GI Fellows Didactic Lecture Series, David Geffen School of Medicine at UCLA, Los Angeles, CA, 8/10/2001

Colorectal Cancer, Fellows Didactic Lecture Series, David Geffen School of Medicine at UCLA, Los Angeles, CA, 10/18/2002

Molecular Basis of Pancreatic Cancer, Fellows Didactic Lecture Series, David Geffen School of Medicine at UCLA, Los Angeles, CA, 8/22/2003

Hyperplastic polyps and HNPCC, Fellows Didactic Lecture Series, David Geffen School of Medicine at UCLA, Los Angeles, CA, 9/24/2004

NERD 2004, Janssen Pharmaceuticals, Los Angeles Regional Clinical Conference, Los Angeles, CA, 10/28/2004

GI Mucosal Biopsy Lecture, Boston-Scientific Regional Talk Series, 10/25/2007

Panel discussant on Emerging Science in GI Cancer, ISGIO, International Society of Gastrointestinal Oncology, Philadelphia, PA, 10/2/2009

Seminar Invitations from Other Institutions

Pancreatic Cancer, 6th Annual Young Investigators' Conference, ASGE, Monterey, CA, 2001

Pancreatic Cancer, 7th Annual Young Investigators' Conference, ASGE, Indian Wells, CA, 2002

GPCR signaling in pancreatic cancer, Gastroenterology Grand Rounds, University of Color, Denver, CO, 2003

GPCR signaling in pancreatic cancer, Gastroenterology Grand Rounds, UT Southwestern Med, Dallas, TX, 2003

Pancreatic Cancer, 8th Annual Young Investigators' Conference, ASGE, Phoenix, AZ, 2003

GPCR signaling in pancreatic cancer, Gastroenterology Grand Rounds, Mayo Clinic, Rochester, MN, 2004

GPCR signaling in pancreatic cancer, Division of Internal Medicine, The University of T, Houston, TX, 2004

Pancreatic Cancer, 9th Annual Young Investigators' Conference, ASGE, Huntington Beach, CA, 2004

GPCR mediated mitogenic signaling in pancreatic cancer, Texas Gulf Coast Digestive Diseases Center, Baylor College of Medicine, Houston, TX, 2005

GPCR signaling in pancreatic cancer, Gastroenterology Grand Rounds, Sepulveda VAMC, North Hills, CA, 2005

GPCR signaling in pancreatic cancer, CURE: DDRRC Grand Rounds, UCLA, Los Angeles, CA, 2005

Pancreatic Cancer, Gastroenterology Grand Rounds, Sepulveda VAMC, North Hills, CA, 2005

Pancreatic Cancer, 4th Annual REGAL Awards, ASGE, San Francisco, CA, 2005

Invited Speaker, UTMB Sealy Cancer Center, Galveston, TX, 2007

Invited Speaker, Oklahoma University Health Sciences Center, Oklahoma City, OK, 2007

GPCR signaling in pancreatic cancer, GI Conference, UT Southwestern, Dallas, TX, 11/16/2007

GPCR mediated signaling in pancreatic cancer, UAB, Birmingham, AL, 2/26/2008

GPCR mediated signaling in pancreatic cancer, Mayo Clinic-Jacksonville, Jacksonville, FL, 3/13/2008

Biological role of Lipocalin 2 in pancreatic cancer: a novel early biomarker, Texas Digestive Diseases Center, Baylor College of Medicine, Houston, TX, 4/3/2008

CXC-chemokines/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer, Texas Medical Center Digestive Disease Center, Baylor College of Medicine, Houston, TX, 2/12/2009

G protein-coupled receptor mediated signaling pathways in pancreatic cancer: implications for therapy, Georgetown University Medical Center, Washington, D.C., DC, 4/7/2009

G protein-coupled receptor mediated signaling pathways in pancreatic cancer: implications for therapy, Saha Institute of Nuclear Physics, India, Calcutta, West Bengal, India, 6/25/2009

CXC-chemokines/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer, University of Calcutta, India, Calcutta, West Bengal, India, 7/1/2009

CXC-chemokines/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer, Drais Pharmaceuticals, Inc., Bridgewater, NJ, 7/13/2009

Lectureships and Visiting Professorships

N/A

Other Presentations at State and Local Conferences

Diseases of the Pancreas, David Geffen School of Medicine at UCLA, Los Angeles, CA, 3/13/2000

NERD Update, Astra Pharmaceuticals, L.P. Los Angeles Regional Consultants Conference, Los Angeles, CA, 10/26/2000

Uninvestigated Dyspepsia, Janssen Pharmaceuticals, Los Angeles Regional Clinical Conference, 7/26/2001

MALT lymphoma, Fellows Didactic Lecture Series, David Geffen Sch, Los Angeles, CA, 8/10/2001

Molecular Basis of Cancer, Fellows Didactic Lecture Series, David Geffen Sch, Los Angeles, CA, 8/10/2001

Colorectal Cancer, Fellows Didactic Lecture Series, David Geffen Sch, Los Angeles, CA, 10/18/2002

Molecular Basis of Pancreatic Cancer, Fellows Didactic Lecture Series, David Geffen Sch, Los Angeles, CA, 8/22/2003

Hyperplastic Polyps and HNPCC, Fellows Didactic Lecture Series, David Geffen Sch, Los Angeles, CA, 9/24/2004

NERD 2004, Janssen Pharmaceuticals, Los Angeles Regional Clinical Conference, Los Angeles, CA, 10/28/2004

Medical Issues in Cancer Survivors Roundtable Discussion, Medical Issues in Cancer Survivors, UT MD Anderson Cancer Center, UT MD Anderson Cancer Center, Houston, TX, 2/6/2009

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American Association for the Advancement of Science
Member, 1991–1998

New York Academy of Sciences
Member, 1992–1995

American Association for the Study of Liver Diseases
Member, 1998–2005

American College of Gastroenterology
Member, 1998–2005

American Gastroenterology Association
Member, 1998–present

American Pancreatic Association
Member, 2003–present

Gastroenterology Research Group
Member, 2003–present

American Association for Cancer Research
Member, 2004–present

International Society of Gastrointestinal Oncology
Member, 2006–present

Society of Translational Cancer Research
Member, 2006–present

Texas Society of Gastrointestinal Endoscopy, Austin, TX
Member, 2009–present

Local/State

Harris County Medical Society, Houston, TX
Member, 2005–present

Texas Medical Society, Houston, TX
Member, 2005–present

UNIQUE ACTIVITIES

1. Teaching middle school students Mathcounts and Science on the weekends for state competitions.
2. Teaching bengali to students of Indian origin.
3. Past Secretary of Bangla Pathshala, a non-profit organization that is involved with teaching bengali to students of Indian origin.
4. Member and volunteer, IACAN (Indian Association of Cancer Network), a non-profit organization for helping Indian cancer patients in Houston, TX.

DATE OF LAST CV UPDATE

10/21/2010